Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WTX-124 Monotherapy and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT05479812Phase 1Completed
- Sponsor
- Werewolf Therapeutics, Inc.
- Start
- Aug 2022
- Primary completion
- Apr 2026
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of WTX-124 in solid tumor, renal cell carcinoma (RCC), melanoma and 2 more (8 arms), sponsored by Werewolf Therapeutics, Inc. Primary endpoints: Incidence of Dose Limiting Toxicities at 4 weeks, Incidence of treatment emergent adverse events at 24 months and 2 more. Started Aug 2022; status: completed.
02
Drugs
WTX-124
03
Conditions
solid tumorrenal cell carcinoma (RCC)melanomasquamous cell carcinoma (SCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05479812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05479812.